Innovative uses of rituximab in dermatology

Dermatologic Clinics

Volumn 28, Issue 3, 2010, Pages 547-557

  Carr, David R ^a   Heffernan, Michael P ^b  

^a WRIGHT STATE UNIVERSITY   (United States)

^b Central Dermatology   (United States)

Author keywords

Biologics; Dermatology; Rituximab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3 ANTIBODY; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

B CELL LYMPHOMA; BULLOUS PEMPHIGOID; CANCER RECURRENCE; DERMATOLOGY; DERMATOMYOSITIS; DRUG DOSE REDUCTION; DRUG TOLERABILITY; EPIDERMOLYSIS BULLOSA ACQUISITA; GRAFT VERSUS HOST REACTION; HUMAN; LARGE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE CYCLE TREATMENT; OFF LABEL DRUG USE; PARANEOPLASTIC PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PRIMARY CUTANEOUS FOLLICLE CENTER LYMPHOMA; PRIORITY JOURNAL; REVIEW; SKIN LUPUS ERYTHEMATOSUS; SKIN LYMPHOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; OFF-LABEL USE; SKIN DISEASES; THERAPIES, INVESTIGATIONAL;

EID: 77953264702     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2010.03.002     Document Type: Review

References (133)

1. Reff M.E., Carner K., Chambers K.S., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83(2):435-445.
2. Grillo-Lopez A.J. Rituximab: an insider's historical perspective. Semin Oncol 2000, 27(6 Suppl. 12):9-16.
3. McDonald V., Leandro M. Rituximab in non-haematological disorders of adults and its mode of action. Br J Haematol 2009, 146:233-246.
4. Stashenko P., Nadler L.M., Hardy R., et al. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980, 125(4):1678-1685.
5. Maloney D.G., Grillo-Lopez A.J., White C.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90(6):2188-2195.
6. Maloney D.G., Liles T.M., Czerwinski D.K., et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994, 84(8):2457-2466.
7. Johnson P.W., Glennie M.J. Rituximab: mechanisms and applications. Br J Cancer 2001, 85(11):1619-1623.
8. Olszewski A.J., Grossbard M.L. Empowering targeted therapy: lessons from rituximab. Sci STKE 2004, 2004(241):pe30.
9. Cartron G., Watier H., Golay J., et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004, 104:2635-2642.
10. Anolik J.H., Campbell D., Felger R.E., et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003, 48:455-459.
11. Maloney D.G., Grillo-Lopez A.J., Bodkin D.J., et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997, 15:3266-3274.
12. Hainsworth J.D. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. Arthritis Res Ther 2003, 5(Suppl 4):S12-S16.
13. Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006, 54(5):1390-1400.
14. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16(8):2825-2833.
15. Looney R.J., Anolik J.H., Campbell D., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50(8):2580-2589.
16. Schmidt E., Hennig K., Mengede C., et al. Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol 2009, 132:334-341.
17. Fogarty G.B., Bayne M., Bedford P., et al. Three cases of activation of cutaneous squamous cell carcinoma during treatment with prolonged administration of rituximab. Clin Oncol 2006, 18(2):155-156.
18. Tesfa D., Gelius T., Sander B., et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol 2008, 25:374-379.
19. Rios-Fernandez R., Gutierrez-Salmeron M.T., Callejas-Rubio J.L., et al. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br J Dermatol 2007, 157:1271-1273.
20. Jones R.B., Ferraro A.J., Chaudhry A.N., et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009, 60(7):2156-2168.
21. Food and Drug Administration FDA warns of safety concern regarding Rituxan in new patient population 2006, [online], Available at:, Accessed February 20, 2007. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01532.html.
22. Carson K.R., Evens A.M., Richey E.A., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood 2009, 113(20):4834-4840.
23. Looney R.J., Anolik J., Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004, 16(3):180-185.
24. Silverman G.J., Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003, 48(6):1484-1492.
25. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350(25):2572-2581.
26. Salopek T.G., Logsetty S., Tredget E.E. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002, 47(5):785-788.
27. Dupuy A., Viguier M., Bedane C., et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004, 140(1):91-96.
28. Goebeler M., Herzog S., Brocker E.B., et al. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 2003, 149(4):899-901.
29. Herrmann G., Hunzelmann N., Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol 2003, 148(3):602-603.
30. Cooper H.L., Healy E., Theaker J.M., et al. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clin Exp Dermatol 2003, 28(4):366-368.
31. Espana A., Fernandez-Galar M., Lloret P., et al. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol 2004, 50(6):974-976.
32. Mouquet H., Musett P., Gougeon M.L., et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 2008, 128:2859-2869.
33. Nagel A., Podstawa E., Eickmann M., et al. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol 2009, 129:2202-2210.
34. Virgolini L., Marzocchi V. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory Pemphigus vulgaris: report of a case. Haematologica 2003, 88(7):ELT24.
35. Arin M.J., Engert A., Krieg T., et al. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005, 153(3):620-625.
36. Belgi A.S., Azeez M., Hoyle C., et al. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol 2006, 31(1):143.
37. Esposito M., Capriotti E., Giunta A., et al. Long-lasting remission of pemphigus vulgaris treated with rituximab. Acta Derm Venereol 2006, 86(1):87-89.
38. Kong H.H., Prose N.S., Ware R.E., et al. Successful treatment of refractory childhood pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol 2005, 22(5):461-464.
39. Morrison L.H. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 2004, 51(5):817-819.
40. Niedermeier A., Worl P., Barth S., et al. Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol 2006, 16(3):266-270.
41. Schmidt E., Herzog S., Brocker E.B., et al. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 2005, 153(2):449-451.
42. Wenzel J., Bauer R., Bieber T., et al. Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants. Acta Derm Venereol 2005, 85(2):185-186.
43. Ahmed A.R., Spigelman Z., Cavacini L.A., et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006, 355:17772-17779.
44. Borel C., Launay F., Garrouste C., et al. Rev Med Interne 2007, DOI:10.1016/j.revmed.2006.11.012 [in French].
45. Schmidt E., Seitz C.S., Benoit S., et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007, 156:352-356.
46. Schmidt E., Goebeler M., Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009, 1173:683-691.
47. Schmidt E., Klinker E., Opitz A., et al. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 2003, 148:1222-1229.
48. Shimanovich I., Nitschke M., Rose C., et al. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008, 158:382-388.
49. Schmidt E., Goebeler M. Use of CD-20-directed therapy in autoimmune skin diseases. Exp Rev Dermatol 2008, 3:259-278.
50. Schmidt E., Brocker E.B., Goebler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 2008, 34:56-64.
51. Joly P., Mouquet H., Roujeau J.C., et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007, 357:545-552.
52. Ahmed A.R., Avram M.M., Duncan L.M. Case records of the Massachusetts general hospital. Weekly clinicopathological exercises. Case 23-2003. A 79-year-old woman with gastric lymphoma and erosive mucosal and cutaneous lesions. N Engl J Med 2003, 349(4):382-391.
53. Borradori L., Lombardi T., Samson J., et al. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2001, 137(3):269-272.
54. Heizmann M., Itin P., Wernli M., et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 2001, 66(2):142-144.
55. Quian S.X., Li J.Y., Hong M., et al. Nonhematological autoimmunity (glomerulosclerosis, paraneoplastic pemphigus and paraneoplastic neurological syndrome) in a patient with chronic lymphocytic leukemia: diagnosis, prognosis and management. Leuk Res 2009, 33:500-509.
56. Barnadas M., Roe E., Brunet S., et al. Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature. J Eur Acad Dermatol Venereol 2006, 20(1):69-74.
57. Van Rossum M.M., Verhaegen N.T., Jonkman M.F., et al. Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities. Leuk Lymphoma 2004, 45(11):2327-2332.
58. Schadlow M.B., Anhalt G.J., Sinha A.A. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol 2003, 2(5):564-567.
59. Hoque S.R., Black M.M., Cliff S. Paraneoplastic pemphigus associated with CD20-positive follicular non-Hodgkin's lymphoma treated with rituximab: a third case resistant to rituximab therapy. Clin Exp Dermatol 2007, 32:172-175.
60. Meijs M., Mekkes J., van Noesel C., et al. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma without Castleman's disease; treatment with rituximab. Int J Dermatol 2008, 47:632-634.
61. Schierl M., Foedinger D., Geissler K., et al. Paraneoplastic pemphigus despite treatment with rituximab, fludarabine, and cyclophosphamide in chronic lymphocytic leukemia. Eur J Dermatol 2008, 18(6):717-718.
62. Schmidt E., Benoit S., Brocker E.B., et al. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol 2006, 142(2):147-150.
63. Crichlow S.M., Mortimer N.J., Harman K.E. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol 2007, 156:194-196.
64. Wallet-Faber N., Franck N., Batteux F., et al. Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab. Dermatology 2007, 215(3):252-255.
65. Niedermeier A., Eming R., Pfutze M., et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol 2007, 143:192-198.
66. Sadler, Schafleitner B., Lanschuetzer C., et al. Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. Br J Dermatol 2007, 157:417-418.
67. Mercader P., Rodenas J.M., Pena A., et al. Fatal Pseudomona pneumonia following rituximab therapy in a patient with epidermolysis bullosa acquisita. J Eur Acad Dermatol Venereol 2007, 21:1141-1142.
68. Saouki Z., Papadopoulos A., Kaiafa G., et al. A new approach on bullous pemphigoid therapy. Ann Oncol 2008, 19(4):825-826.
69. Schulze J., Bader P., Henke U., et al. Severe bullous pemphigoid in an infant - successful treatment with rituximab. Pediatr Dermatol 2008, 25(4):462-465.
70. Reguiai Z., Tchen T., Perceau G., et al. Efficacy of rituximab in a case of refractory bullous pemphigoid. Ann Dermatol Venereol 2009, 136(5):431-434.
71. Chee R., Nagendran V., Bansal A., et al. B-cell targeted therapy alone may not be effective in bullous pemphigoid. Clin Exp Dermatol 2006, 32:111-112.
72. Schumann T., Schmidt E., Booken N., et al. Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab. Acta Derm Venereol 2009, 89:101-102.
73. Taverna J.A., Lerner A., Bhawan J., et al. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab. J Drugs Dermatol 2007, 6(7):731-732.
74. Ross A.H., Jaycock P., Cook S.D., et al. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br J Ophthalmol 2009, 93(4):421-422.
75. Senff N.J., Noordijk E.M., Kim Y.H., et al. European organization for research and treatment of cancer and international society for cutaneous lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008, 112:1600-1609.
76. Morales A.V., Advani R., Horwitz S.M., et al. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. J Am Acad Dermatol 2008, 59:953-957.
77. Kyrtsonis M.C., Siakantaris M.P., Kalpadakis C., et al. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol 2006, 77:300-303.
78. Valencak J., Weihsengruber F., Rappersberger K., et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol 2009, 20:326-330.
79. Fink-Puches R., Wolf I.H., Zalaudek I., et al. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol 2005, 52(5):847-853.
80. Kerl K., Prins C., Saurat J.H., et al. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol 2006, 155:1197-1200.
81. Lozzi G.P., Coletti G., Peris K. Persistent CD20-negative primary cutaneous marginal zone lymphoma after treatment with intralesional rituximab therapy. J Am Acad Dermatol 2008, 59(5):S110-S112.
82. Gellrich S., Muche J.M., Wilks A., et al. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas-an applicational observation. Br J Dermatol 2005, 153(1):167-173.
83. Heinzerling L.M., Urbanek M., Funk J.O., et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000, 89(8):1835-1844.
84. Lacouture M.E., Baron J.M., Jani A.B., et al. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma. Cancer 2000, 89:1835-1844.
85. Aboulafia D.M. Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab). Am J Clin Oncol 2001, 24:237-240.
86. Bonnekoh B., Schulz M., Franke I., et al. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab. J Cancer Res Clin Oncol 2002, 128:161-166.
87. Garbea A., Dippel E., Hildenbrand R., et al. Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer. Br J Dermatol 2002, 146:144-147.
88. Zinzani P.L., Stefoni V., Alinari L., et al. Rituximab in heavily pretreated cutaneous B-cell lymphoma. Leuk Lymphoma 2003, 44:1637-1638.
89. Sabroe R.A., Child F.J., Woolford A.J., et al. Rituximab in cutaneous B-cell lymphoma: a report of two cases. Br J Dermatol 2000, 143:157-161.
90. Grange F., Beylot-Barry M., Courville P., et al. Primary cutaneous diffuse large B-cell lymphoma, leg type. Arch Dermatol 2007, 143(9):1144-1150.
91. Levine T.D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005, 52(2):601-607.
92. Chung L., Genovese M.C., Fiorentino D.F. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007, 143:763-767.
93. Greenberg S.A., Amato A.A. Uncertainties in the pathogenesis of adult dermatomyositis. Curr Opin Neurol 2004, 17(3):359-364.
94. Dalakas M.C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362(9388):971-982.
95. Santmyire-Rosenberger B., Dugan E.M. Skin involvement in dermatomyositis. Curr Opin Rheumatol 2003, 15(6):714-722.
96. Kieu V., O'Brien T., Yap L.M., et al. Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab. Australas J Dermatol 2009, 50:202-206.
97. Uthman I., Taher A., Abbas O., et al. Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case. Dermatology 2008, 216(3):257-259.
98. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-vs.-host disease. Blood 2006, 108(2):756-762.
99. Canninga-van Dijk M.R., van der Straaten H.M., Fijnheer R., et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004, 104(8):2603-2606.
100. Okamoto M., Okano A., Akamatsu S., et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006, 20(1):172-173.
101. Ratanatharathorn V., Ayash L., Reynolds C., et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003, 9(8):505-511.
102. Carella A.M., Biasco S., Nati S., et al. Rituximab is effective for extensive steroid-refractory chronic graft-vs-host-disease. Leuk Lymphoma 2007, 48(3):623-624.
103. Zaja F., Bacigalupo A., Patriarca F., et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007, 40(3):273-277.
104. Mohty M., Marchetti N., El-Cheikh J., et al. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 2008, 41(10):909-911.
105. Teshima T., Nagafuji K., Henzan H., et al. Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. Int J Hematol 2009, 90(2):253-260.
106. Shimabukuro-Vornhagen A., Hallek M.J., Storb R.F., et al. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009, 114(24):4919-4927.
107. Gilliam A.C. Update on graft versus host disease. J Invest Dermatol 2004, 123(2):251-257.
108. Rouquette-Gally A.M., Boyeldieu D., Prost A.C., et al. Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients. Transplantation 1988, 46(2):238-240.
109. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005, 105(7):2973-2978.
110. Miklos D.B., Kim H.T., Zorn E., et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004, 103(1):353-359.
111. Schultz K.R., Paquet J., Bader S., et al. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995, 16(2):289-295.
112. Kamble R., Oholendt M., Carrum G. Rituximab responsive refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2006, 12:1201-1202.
113. Kebriaei P., Saliba R.M., Ma C., et al. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 2006, 38(3):203-209.
114. Shimoni A., Hardan I., Avigdor A., et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003, 122(3):457-464.
115. Christopeit M., Schuette V., Behre G. Rituximab reduces the incidence of acute graft versus host disease and delays CD3+CD4+ Lymphocyte recovery. Blood 2007, 110(11):5005.
116. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111(12):5530-5536.
117. Glass B., Hasenkamp J., Gorlitz A., et al. Rituximab for graft-versus-host-disease-prophylaxis after allogeneic stem cell transplantation given as treatment of high risk relapse of aggressive lymphoma: results of a randomized phase II Study. Blood 2008, 112(11):1974.
118. Cheung C.M., Murray P.I., Savage C.O. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol 2005, 89:1542.
119. Bachmeyer C., Cadranel J.F., Demontis R. Rituximab is an alternative in a case of contra-indication of cyclophosphamide in Wegener's granulomatosis. Nephrol Dial Transplant 2005, 20:1274.
120. Ferraro A.J., Day C.J., Drayson M.T., et al. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant 2005, 20:622-625.
121. Kallenback M., Duan H., Ring T. Rituximab induced remission in a patient with Wegener's granulomatosis. Nephron Clin Pract 2005, 99:c92-c96.
122. Specks U., Freeze F.C., McDonald T.J., et al. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthiritis Rheum 2001, 44:2836-2840.
123. Omdal R., Wildhagen K., Hansen T., et al. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 2005, 34:229-232.
124. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005, 257:540-548.
125. Keogh K.A., Wylam M.E., Stone J.H., et al. Induction of remission by B-lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:262-268.
126. Tamura N., Matsudaira R., Hirashima M., et al. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 2007, 46:409-414.
127. Brihaye B., Aouba A., Pagnoux C., et al. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007, 25(Suppl 44):S23-S27.
128. Keogh K.A., Ytterberg S.R., Fervenza F.C., et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label trial. Am J Respir Crit Care Med 2006, 173:180-187.
129. Aries P.M., Hellmich B., Reinhold-Keller E., et al. High dose intravenous azathioprine pulse treatment in refractory Wegener's granulomatosis. Rheumatology 2004, 43:1307-1308.
130. Stasi R., Stipa E., Del Poeta G., et al. Lon-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology 2006, 45(11):1432-1436.
131. Smith K.G., Jones R.B., Burns S.M., et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis. Arthritis Rheum 2006, 54(9):2970-2982.
132. Sneller M.C. Rituximab and Wegener's granulomatosis: are B-cells a target in vasculitis treatment. Arthritis Rheum 2005, 52:1-5.
133. Wong C. Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence?. Nephrol Dial Transplant 2007, 22:32-36.